Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 72INDUSTRY 38NETWORK 3FED 3OTHER_GOV 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Adenocarcinoma 1

Interventions

Radiotherapy 34Gemcitabine 24Docetaxel 24bicalutamide 23Goserelin 21Paclitaxel 19Cisplatin 19Doxorubicin 18Carboplatin 18Flutamide 17Leuprolide 16Radiotherapy, Conformal 13Etoposide 13Filgrastim 12Prednisone 11Gene Expression Profiling 11Gonadotropin-Releasing Hormone 10Radiotherapy, Intensity-Modulated 9Vincristine 8Vinblastine 8Triptorelin Pamoate 8Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Buserelin 8Androgen Antagonists 8Surgical Procedures, Operative 7Radiation 7Polymerase Chain Reaction 7Methotrexate 7Estramustine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × apalutamide × Genitourinary × Clear all
NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT03488810 2020-08-17

ARN-509

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡